

溫州康寧書院股份有限公司

Wenzhou Kan Ning Shu Yuan Co., Ltd.

(A joint stock limited liability company incorporated in the

2 FINANCIAL HIGHLIGHTS

2.1 Principal Financial Data and Indicators

	For the six months ended June 30,	
	2020 (RMB'000) (Unaudited)	2019 (RMB'000) (Unaudited)
Revenue	465,150	378,910
Cost of services	39,404	52,661
Operating expenses	(10,503)	(7,120)
Operating income	28,901	45,541
Financial income	36,410	52,064
Financial expenses	(7,509)	(6,523)
Profit before income tax		
Income tax		
Profit after income tax		
	As at	
	June 30, 2020 (RMB'000) (Unaudited)	June 30, 2019 (RMB'000) (Unaudited)
Assets	2,274,908	2,117,352
Liabilities	960,485	855,843
Equity	1,314,423	1,261,509
Profit after income tax	1,186,459	1,164,484
Other comprehensive income	127,964	97,025

4.1 Financial Review

1. 若 $f(x)$ 在 x_0 处可导, 则 $f(x)$ 在 x_0 处连续; ()
 2. 若 $f(x)$ 在 x_0 处连续, 则 $f(x)$ 在 x_0 处可导; ()
 3. 若 $f(x)$ 在 x_0 处不可导, 则 $f(x)$ 在 x_0 处不连续; ()
 4. 若 $f(x)$ 在 x_0 处可导, 则 $f(x)$ 在 x_0 处有唯一切线. ()

4

... ..

... ..

... ..

... k ...

	For the six months ended June 30,	
	2020 (Unaudited)	2019 (Unaudited)
In Patients		
Number of inpatients	6,853	5,593
Revenue from inpatient services (RMB'000)	1,240,393	1,012,333
Revenue from inpatient services (%)	83.1	84.9
Revenue from inpatient services (RMB'000)	1,030,392	859,061
Revenue from inpatient services (RMB'000)	324,990	251,945
Revenue from inpatient services (RMB'000)	315	293
Revenue from inpatient services (RMB'000)	53,841	50,926
Revenue from inpatient services (RMB'000)	52	59
Total inpatient revenue (RMB'000)	378,831	302,871
Total average inpatient spending per bed-day (RMB)	368	353
Out Patients		
Number of outpatients	125,852	105,986
Revenue from outpatient services (RMB'000)	12,761	11,635
Revenue from outpatient services (RMB'000)	101	110
Revenue from outpatient services (RMB'000)	47,294	45,704
Revenue from outpatient services (RMB'000)	376	431
Total outpatient revenue (RMB'000)	60,055	57,339
Total average outpatient spending per visit (RMB)	477	541
Total treatment and general healthcare services revenue (RMB'000)	337,751	263,580
Total pharmaceutical sales revenue (RMB'000)	101,135	96,630

25.1% 378.8 2019, 19.9%
 : ()
 ; ()
 4.2%.
 86.3% (30, 2019: 84.1%).

4.7% 60.1 2019,
 18.7%.
 13.7% (30, 2019: 15.9%).

28.1% 2019,
 77.0% (30,
 2019: 73.2%);
 4.7%
 2019, 23.0%
 (30, 2019: 26.8%), :
 14.2% (30, 2019: 16.8%),
 78.8% (30, 2019:
 79.7%).

;
 k
 :

	For the six months ended June 30,	
	2020 (RMB'000) (Unaudited)	2019 (RMB'000) (Unaudited)
Cost of revenue of owned hospitals	112,156	101,813
	110,048	91,091
	15,297	14,119
	37,019	30,236
	18,390	16,577
	11,647	7,807
	18,906	18,290
Cost of revenue of owned hospitals	323,463	279,933

323.5, 2019, 15.6%
 : ()
 28.1%
 2019; ()
 ; ()
 .

34.7% (30, 2019: 36.4%).
 34.0% (30, 2019: 32.5%).

4.1.2 Gross Profit and Gross Profit Margin

2020.	128.3	39.4%
2019.	115.4	43.8%
2020.	k	

	For the six months ended June 30,	
	2020 (Unaudited)	2019 ()
	29.7%	25.1%
	14.9%	14.5%
	26.3%	22.3%
	47.1%	62.8%
Consolidated gross profit margin	27.6%	24.3%

27.6% (30, 2019: 24.3%), 4.6
2019,

4.1.3 Tax and Surcharge

2.0
30, 2019: 0.8

4.1.4 Selling Expenses

3.7
30, 2019: 4.5
0.8
0.8%
30, 2019: 1.2%.

4.1.5 Administrative Expenses

4.1.7 Finance Expenses – Net

'Finance expenses' are the costs of borrowing money, such as interest on bank loans, overdrafts, and credit cards. 'Finance income' is the income from investments, such as interest on savings accounts, dividends from shares, and rental income from property. 

16.1 (30, 2019: 10.7), 3.5% (30, 2019: 2.8%). A 30, 2020 31, 2019, 30.3 21.4 8.6% 7.1%

4.1.9 Credit Impairment Losses

16.1 (30, 2019: 10.7), 3.5% (30, 2019: 2.8%). A 30, 2020 31, 2019, 30.3 21.4 8.6% 7.1%

4.1.10 Non-Operating Income (Expenses) and Other Gains

16.1 (30, 2019: 10.7), 3.5% (30, 2019: 2.8%). A 30, 2020 31, 2019, 30.3 21.4 8.6% 7.1%

4.1.11 Income Tax Expense

At December 31, 2019, the Company's income tax expense was \$7.1 million, or 10.5% of pretax income, compared to \$10.5 million, or 13.5% of pretax income, at December 31, 2018. The effective tax rate for 2019 was 47.5%, compared to 26.7% for 2018. The effective tax rate for 2019 was higher than the statutory rate of 21.0% due to the Company's tax loss carryforwards and other tax attributes.

4.2 Financial Position

4.2.1 Inventory

At December 31, 2020, the Company's inventory was \$33.9 million, or 33.9% of total assets, compared to \$23.6 million, or 23.6% of total assets, at December 31, 2019. The inventory was primarily composed of raw materials, work-in-progress, and finished goods. The inventory was primarily composed of raw materials, work-in-progress, and finished goods. The inventory was primarily composed of raw materials, work-in-progress, and finished goods.

At December 31, 2020, the Company's inventory was \$33.9 million, or 33.9% of total assets, compared to \$23.6 million, or 23.6% of total assets, at December 31, 2019. The inventory was primarily composed of raw materials, work-in-progress, and finished goods. The inventory was primarily composed of raw materials, work-in-progress, and finished goods.

At December 31, 2020, the Company's inventory was \$33.9 million, or 33.9% of total assets, compared to \$23.6 million, or 23.6% of total assets, at December 31, 2019. The inventory was primarily composed of raw materials, work-in-progress, and finished goods. The inventory was primarily composed of raw materials, work-in-progress, and finished goods.

At December 31, 2020, the Company's inventory was \$33.9 million, or 33.9% of total assets, compared to \$23.6 million, or 23.6% of total assets, at December 31, 2019. The inventory was primarily composed of raw materials, work-in-progress, and finished goods. The inventory was primarily composed of raw materials, work-in-progress, and finished goods.

At December 31, 2020, the Company's inventory was \$33.9 million, or 33.9% of total assets, compared to \$23.6 million, or 23.6% of total assets, at December 31, 2019. The inventory was primarily composed of raw materials, work-in-progress, and finished goods. The inventory was primarily composed of raw materials, work-in-progress, and finished goods.

At December 31, 2020, the Company's inventory was \$33.9 million, or 33.9% of total assets, compared to \$23.6 million, or 23.6% of total assets, at December 31, 2019. The inventory was primarily composed of raw materials, work-in-progress, and finished goods. The inventory was primarily composed of raw materials, work-in-progress, and finished goods.

At December 31, 2020, the Company's inventory was \$33.9 million, or 33.9% of total assets, compared to \$23.6 million, or 23.6% of total assets, at December 31, 2019. The inventory was primarily composed of raw materials, work-in-progress, and finished goods. The inventory was primarily composed of raw materials, work-in-progress, and finished goods.

At December 31, 2020, the Company's inventory was \$33.9 million, or 33.9% of total assets, compared to \$23.6 million, or 23.6% of total assets, at December 31, 2019. The inventory was primarily composed of raw materials, work-in-progress, and finished goods. The inventory was primarily composed of raw materials, work-in-progress, and finished goods.

At December 31, 2020, the Company's inventory was \$33.9 million, or 33.9% of total assets, compared to \$23.6 million, or 23.6% of total assets, at December 31, 2019. The inventory was primarily composed of raw materials, work-in-progress, and finished goods. The inventory was primarily composed of raw materials, work-in-progress, and finished goods.

4.2.2 Accounts Receivables

At December 31, 2020, Accounts Receivable was 352.6 million (December 31, 2019: 310.5 million), an increase of 14.5% from 2019, primarily due to the increase in sales volume. The aging of Accounts Receivable at December 31, 2020, is as follows:

Age	2020 (million)	2019 (million)
Within 30 days	133	146

4.2.3 Other Receivables and Prepayments

At December 31, 2020, Other Receivables and Prepayments were 88.4 million (December 31, 2019: 68.7 million).

4.2.4 Investment Properties

At December 31, 2020, Investment Properties were 107.1 million (December 31, 2019: 110.9 million), a decrease of 3.4 million, primarily due to the decrease in the fair value of the investment properties. The fair value of the investment properties at December 31, 2020, is as follows:

Investment Property	2020 (million)	2019 (million)
Investment Property A	302	303
Investment Property B	304	303

The fair value of the investment properties at December 31, 2020, is as follows:

Investment Property	2020 (million)	2019 (million)
Investment Property A	302	303
Investment Property B	304	303

At December 31, 2020, the fair value of the investment properties was 107.1 million (December 31, 2019: 110.9 million), a decrease of 3.4 million, primarily due to the decrease in the fair value of the investment properties. The fair value of the investment properties at December 31, 2020, is as follows:

Investment Property	2020 (million)	2019 (million)
Investment Property A	302	303
Investment Property B	304	303

The fair value of the investment properties at December 31, 2020, is as follows:

Investment Property	2020 (million)	2019 (million)
Investment Property A	302	303
Investment Property B	304	303



29, 2043,

462.9()24 (2/ 11/) (15)

4.2.8 Contract Liability

As at June 30, 2020, the Company's contract liability was RMB10.8 million (June 30, 2019: RMB8.6 million).

4.2.9 Other Payables

As at June 30, 2020, the Company's other payables were RMB93.5 million (June 30, 2019: RMB133.3 million).

4.3 Liquidity and Capital Resources

The following table summarizes the Company's cash flows for the six months ended June 30, 2020 and 2019:

	For the six months ended June 30,	
	2020 (RMB'000) (Unaudited)	2019 (RMB'000)
Cash generated from operating activities	17,799	4,157
Cash used in investing activities	(76,436)	(75,880)
Cash generated from financing activities	94,945	(25,941)
Change in cash and cash equivalents	36,424	(98,423)

4.3.1 Net Cash Generated from Operating Activities

For the six months ended June 30, 2020, the Company's net cash generated from operating activities was RMB17.8 million, compared with RMB28.9 million for the six months ended June 30, 2019. The increase was primarily due to the increase in net income of RMB16.1 million (2019: RMB60.0 million) and the decrease in cash used in operating activities of RMB90.9 million (2019: RMB14.5 million).

4.3.2 Net Cash Used in Investing Activities

For the six months ended June 30, 2020, the Company's net cash used in investing activities was RMB76.4 million, compared with RMB67.1 million for the six months ended June 30, 2019. The increase was primarily due to the increase in cash used in investing activities of RMB76.4 million (2019: RMB67.1 million) and the decrease in cash generated from investing activities of RMB14.5 million (2019: RMB14.5 million).

4.3.3 Net Cash Generated from Financing Activities

At 31, 2020,	94.9	At 31, 2019:	163.5
Decreased by:		Increased by:	
Net cash generated from financing activities	39.1	Net cash generated from financing activities	

4.3.4 Significant Investment, Acquisition and Disposal

At 31, 2020,	30, 2020.	At 31, 2019:	
--------------	-----------	--------------	--

4.4 Indebtedness

4.4.1 Bank Borrowings

At 31, 2020,	k	At 31, 2019:	
473.5	(31, 2019: 310.0)	201.0	
364.5			

4.4.2 Contingent Liability

At 31, 2020,	At 31, 2019:	
--------------	--------------	--

4.4.3 Asset Pledge

At 31, 2020,	At 31, 2019:	
k		

4.4.4 Lease Liabilities

At 31, 2020,	At 31, 2019:	
24.2	186.0	

4.4.5 Financial Instruments

At 31, 2020,	At 31, 2019:	
k		

4.4.6 Exposure to Fluctuation in Exchange Rates

At 30 June 2020, the Group's exposure to exchange rate fluctuations was as follows:

At 30 June 2020, the Group's exposure to exchange rate fluctuations was as follows:

4.4.7 Gearing Ratio

At 30 June 2020, the Group's gearing ratio (total debt divided by total equity) was 42.2% (31, 2019: 40.4%).

4.4.8 Employees and Remuneration Policy

At 30 June 2020, the Group's total number of employees was 3,136 (31, 2019: 2,845). The Group's total remuneration expense for the period ended 30 June 2020 was 149.5 million (30, 2019: 128.1 million). The Group's total remuneration expense for the period ended 30 June 2019 was 98.2 million.

The Group's total remuneration expense for the period ended 30 June 2018 was 13, 2018 (2017 AGM). The Group's total remuneration expense for the period ended 30, 2018 was 29, 2018.

At 30 June 2020, the Group's total remuneration expense for the period ended 30, 2018, was 165, 2018 (2017 AGM). The Group's total remuneration expense for the period ended 30, 2018, was 1,818,529.

A. 15
 A, 26, 2019, 37, 273,161 A 14, 23, 180,516, 0.2391%
 (10.47%).

Category of Personnel	Number of Persons granted (Person)	Number of Shares granted (Share)	Number of grant representing total issued share capital of the Company
	17	142,311	0.1885%
	6	38,204	0.0506%
	23	180,516	0.2391%

(溫州箴言康寧投資管理合夥企業(有限合夥))
 48
 k 48

5 PURCHASE, SALE AND REDEMPTION OF LISTED SECURITIES

2020年12月31日，本公司回购H股899,700股，支付总金额为人民币15,888,990元。				
Repurchase period	Total number of H Shares repurchased	Price paid per share Highest (\$)	Price paid per share Lowest (\$)	Total consideration (\$)
2020	35,000	17.90	17.80	624,200
2020	715,200	18.56	17.70	12,993,510
2020	9,400	16.00	15.80	148,540
2020	140,100	15.30	14.70	2,122,740
	899,700			15,888,990

本公司在2020年12月31日，没有未完成的股份回购计划。

本公司在2020年12月31日，没有未完成的股份出售计划。

6 EVENTS AFTER THE REPORTING PERIOD

自2020年12月31日至2021年3月31日，本公司没有发生任何重大事件。

7 REVIEW OF INTERIM RESULTS

As at the end of the reporting period, the Company's interim results for the period ended 30, 2020, compared with the corresponding period of the previous year, are as follows:

As at the end of the reporting period, the Company's interim results for the period ended 30, 2020, compared with the corresponding period of the previous year, are as follows:

8 INTERIM DIVIDEND

The Company has not declared any interim dividend for the period ended 30, 2020 (corresponding period of the previous year: 30, 2019: Nil).

9 COMPLIANCE WITH CG CODE

The Company has complied with the CG Code throughout the reporting period.

10 ACCOUNTING STANDARDS

The Company has adopted the Accounting Standards issued by the Institute of Cost Accountants of India (ICAI) for the period ended 30, 2020, which are in accordance with the Accounting Standards issued by the Institute of Cost Accountants of India (ICAI) for the period ended 30, 2017, (622 Companies Ordinance).

11 FINANCIAL REPORT

11.1 Accounting Policies

The Company has adopted the Accounting Standards issued by the Institute of Cost Accountants of India (ICAI) for the period ended 30, 2020, which are in accordance with the Accounting Standards issued by the Institute of Cost Accountants of India (ICAI) for the period ended 30, 2017, (622 Companies Ordinance).

The Company has adopted the Accounting Standards issued by the Institute of Cost Accountants of India (ICAI) for the period ended 30, 2020, which are in accordance with the Accounting Standards issued by the Institute of Cost Accountants of India (ICAI) for the period ended 30, 2017, (622 Companies Ordinance).

The Company has adopted the Accounting Standards issued by the Institute of Cost Accountants of India (ICAI) for the period ended 30, 2020, which are in accordance with the Accounting Standards issued by the Institute of Cost Accountants of India (ICAI) for the period ended 30, 2017, (622 Companies Ordinance).

The Company has adopted the Accounting Standards issued by the Institute of Cost Accountants of India (ICAI) for the period ended 30, 2020, which are in accordance with the Accounting Standards issued by the Institute of Cost Accountants of India (ICAI) for the period ended 30, 2017, (622 Companies Ordinance).

11.2 Interim Financial Statement

As at June 30, 2020, the Company's consolidated financial statements were audited by the independent auditor, PricewaterhouseCoopers LLP, and the audit report was issued on July 1, 2020.

11.2.1 Interim Consolidated Income Statement

(Amounts in thousands of Canadian dollars)

		For the six months ended June 30,	
		2020	2019
		(Unaudited)	(Unaudited)
1. Revenue		465,150,452	378,910,291
Cost of sales		(336,864,754)	(286,882,183)
Gross profit		(1,999,246)	(831,972)
Operating expenses		(3,697,157)	(4,476,806)
Operating income		(54,639,015)	(52,890,346)
Other income		(2,637,407)	(2,304,024)
Other expenses		(11,846,196)	(10,198,874)
Income before income taxes		(14,086,629)	(11,068,131)
Income taxes		2,454,371	1,925,426
Income before discontinued operations		5,443,616	6,567,461
Income from discontinued operations		(923,557)	23,549,073
Income before income taxes		(1,019,927)	(2,525,317)
Income taxes		(16,112,650)	(10,730,916)
Income before discontinued operations		-	984,550
Income from discontinued operations		-	984,550

LIABILITIES AND SHAREHOLDERS' EQUITY	June 30, 2020 (Unaudited)	June 30, 2019 (Audited)
Current liabilities		
Accounts payable and accrued liabilities	332,500,000	250,000,000
Accounts receivable	576,686	—
Accounts receivable - related parties	63,565,539	75,554,960
Accounts receivable - other	10,772,528	8,562,126
Accounts receivable - other	23,923,352	36,063,277
Accounts receivable - other	44,736,621	33,430,060
Accounts receivable - other	93,516,092	133,348,712
Accounts receivable - other	66,053,557	79,741,922
Total current liabilities	635,644,375	616,701,057
Non-current liabilities		
Accounts payable and accrued liabilities	100,500,000	20,000,000
Accounts receivable	186,013,332	183,808,151
Accounts receivable - related parties	580,000	2,260,000
Accounts receivable - other	2,000,000	2,000,000
Accounts receivable - other	9,797,371	9,949,267
Accounts receivable - other	25,949,596	21,124,118
Total non-current liabilities	324,840,299	239,141,536
Total liabilities	960,484,674	855,842,593
Shareholders' equity		
Common stock	75,500,000	75,500,000
Preferred stock	826,376,743	824,715,445
Retained earnings	(37,817,508)	(21,721,144)
Accumulated other comprehensive income	33,189,321	33,189,321
Accumulated other comprehensive income	289,210,662	252,800,715
Total equity attributable to shareholders of the Parent company	1,186,459,218	1,164,484,337
Accounts receivable - other	127,964,021	97,024,925
Total shareholders' equity	1,314,423,239	1,261,509,262
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	2,274,907,913	2,117,351,855

11.2.3 Interim Consolidated Statements of Cash Flow

(A. 11.2.3 Interim Consolidated Statements of Cash Flow)

	For the six months ended June 30,	
	2020 (Unaudited)	2019 (Unaudited)
1. Cash flows from operating activities		
Cash received from customers	411,405,749	337,771,543
Cash received from other sources	8,311,056	7,188,089
Sub-total of cash inflows	419,716,805	344,959,632
Cash paid for operating expenses	(174,912,876)	(153,687,796)
Cash paid for interest and dividends	(162,022,960)	(137,201,128)
Cash paid for income taxes	(14,474,391)	(20,832,826)
Cash paid for other operating activities	(50,507,831)	(29,080,692)
Sub-total of cash outflows	(401,918,058)	(340,802,442)
Net cash flows from operating activities	17,798,747	4,157,190
2. Cash flows from investing activities		
Cash received from the sale of property, plant and equipment	30,010,000	447,095
Cash received from the sale of investments	96,370	—
Cash received from the sale of other assets	3,870,905	—
Cash paid for the acquisition of property, plant and equipment	—	1,833,758
Cash paid for the acquisition of investments	—	2,555,426
Sub-total of cash inflows	33,977,275	4,836,279
Cash paid for the acquisition of property, plant and equipment	(67,075,009)	(63,099,075)
Cash paid for the acquisition of investments	(15,145,000)	(13,020,000)
Cash paid for the acquisition of other assets	(25,593,510)	(1,246,349)
Cash paid for other investing activities	(2,600,000)	(3,351,048)
Sub-total of cash outflows	(110,413,519)	(80,716,472)
Net cash flows used in investing activities	(76,436,244)	(75,880,193)

		For the six months ended	
		June 30,	
		2020	2019
		(Unaudited)	(Unaudited)
3. Cash flows from financing activities			
Proceeds from the issuance of bank loans		23,361,500	4,245,000
Proceeds from the issuance of short-term debt			
Proceeds from the issuance of long-term debt			
Proceeds from the issuance of equity		21,771,500	4,245,000
Proceeds from the issuance of other financial instruments		367,285,789	170,000,000
Proceeds from the issuance of other financial instruments		—	—
Sub-total of cash inflows		390,647,289	174,245,000
Payments for the acquisition of property, plant and equipment		(201,900,000)	(146,000,000)
Payments for the acquisition of intangible assets		(8,241,036)	(6,647,896)
Payments for the acquisition of other financial instruments		(85,561,157)	(47,538,263)
Sub-total of cash outflows		(295,702,193)	(200,186,159)
Net cash flows generated from/(used in) financing activities		94,945,096	(25,941,159)
4. Effect of foreign exchange rate changes on cash and cash equivalents		116,743	(758,597)
5. Net increase/(decrease) in cash and cash equivalents		36,424,342	(98,422,759)

11.2.4 Interim Consolidated Statement of Changes in Shareholders' Equity

(Amounts in millions of U.S. dollars)

	Equity attributable to shareholders of the Parent company					Non-controlling interests	Total shareholders' equity
	Share capital	Capital surplus	Less: Treasury stock	Surplus reserve	Retained earnings		
Balance at January 1, 2020	<u>75,500,000</u>	<u>824,715,445</u>	<u>(21,721,144)</u>	<u>33,189,321</u>	<u>252,800,715</u>	<u>97,024,925</u>	<u>1,261,509,262</u>
Net income	-	-	-	-	36,409,947	(7,508,712)	28,901,235
Dividends declared	-	-	-	-	-	21,771,500	21,771,500
Share-based compensation	-	3,914,851	(1,590,000)	-	-	-	2,324,851
Share repurchases	-	(2,253,553)	-	-	-	(1,709,223)	(3,962,776)
Other	-	-	(14,506,364)	-	-	-	(14,506,364)

11.3 Notes to the Interim Financial Statement Prepared in accordance with the China Accounting Standard for Business Enterprises

11.3.1 Accounts Receivable

(Amount in thousands of RMB)

	June 30, 2020 (Unaudited)	June 30, 2019 (Audited)
Accounts receivable	6,750,000	8,250,000
Allowance for doubtful accounts	384,779,056	330,174,215
Accounts receivable, net	391,529,056	338,424,215
Less: Accounts receivable transferred to special purpose vehicle	(38,883,916)	(27,903,603)
Accounts receivable, net of transferred	<u>352,645,140</u>	<u>310,520,612</u>

The accounts receivable transferred to special purpose vehicle at June 30, 2020 and June 30, 2019 are as follows:

	June 30, 2020 (Unaudited)	June 30, 2019 (Audited)
1. Accounts receivable transferred to special purpose vehicle	307,256,118	266,932,953
2. Allowance for doubtful accounts transferred to special purpose vehicle	54,328,309	57,988,407
3. Accounts receivable transferred to special purpose vehicle, net	24,130,088	13,089,001
4. Allowance for doubtful accounts transferred to special purpose vehicle, net	5,814,541	413,854
Accounts receivable transferred to special purpose vehicle, net	<u>391,529,056</u>	<u>338,424,215</u>

Accounts receivable transferred to special purpose vehicle are as follows:

11.3.2 Accounts Payable

$$(A_{\text{eff}}^{\text{eff}} = A_{\text{eff}}^{\text{eff}} \cdot \frac{1}{\sqrt{1 - \frac{v^2}{c^2}}} \cdot \frac{1}{\sqrt{1 - \frac{v^2}{c^2}}})$$

30, 2020 31, 2019

	June 30, 2020 (Unaudited)	June 30, 2019 (Audited)
Operating income	54,973,453	65,881,555
Operating expenses	5,224,098	7,479,995
Operating income before income taxes	2,277,029	1,381,101
Income taxes	578,371	506,880
Income before non-recurring items	276,874	94,816
Non-recurring items	235,714	210,613
Income before income taxes	63,565,539	75,554,960

11.3.3 Revenue and Cost of Sales

$$(A_{\text{eff}}^{\text{eff}}, \mathbf{A}_{\text{eff}}^{\text{eff}}, \mathbf{A}_{\text{eff}}^{\text{eff}}, \mathbf{A}_{\text{eff}}^{\text{eff}})$$

For the six months ended
June 30,
2020 2019
(Unaudited) (4,000)

[illegible]

Revenue and cost of sales from main operations

(Amount in thousands of US dollars)

		For the six months ended June 30, 2020	
		(Unaudited) Revenue from main operations	(Unaudited) Cost of sales from main operations
Revenue		101,134,489	86,044,257
Cost of sales		337,751,259	237,418,788
		<u>438,885,748</u>	<u>323,463,045</u>
		For the six months ended June 30, 2019	
		(Unaudited) Revenue from main operations	(Unaudited) Cost of sales from main operations
Revenue		96,629,883	82,628,810
Cost of sales		263,579,519	197,304,478
		<u>360,209,402</u>	<u>279,933,288</u>

11.3.4 Earnings Per Share

(A) (Decrease) (Increase) (Decrease) (Increase)

() (Decrease) (Increase)

For the six months ended
June 30,
2020 2019
(Unaudited) () ()

Net income		
()		
36,409,947	52,064,124	
72,769,749	73,040,000	
0.50	0.71	

() (Decrease) (Increase) (Decrease) (Increase)

13, 2018, 2,460,000

A

k , 7, 2,460,000 A

30, 2020.

30, 2020, 899,700 k , 73,034,363 k

() (Decrease) (Increase)

(Decrease) (Increase) (Decrease) (Increase)

30, 2020, 36,409,947. 73,034,363. 0.50.

30, 2019, 52,064,124. 73,915,743. 0.70.

11.3.5 Income Tax Expense

(Amounts are in thousands of dollars)

	For the six months ended June 30,	
	2020	2019
	(Unaudited)	(Unaudited)
Income tax expense	23,778,834	14,824,769
Deferred income tax expense	(13,276,086)	(7,704,851)
	<u>10,502,748</u>	<u>7,119,918</u>

The income tax expense for the six months ended June 30, 2020, includes the following components:

	For the six months ended June 30,	
	2020	2019
	(Unaudited)	(Unaudited)
Current income tax expense	39,403,983	52,661,149
Deferred income tax expense		
Federal income tax expense	9,850,996	13,165,287
State income tax expense	579,650	1,158,271
Local income tax expense	121,674	119,184
Other income tax expense	(490,212)	(431,227)
Deferred income tax expense	—	(318,561)
Other income tax expense	440,640	51,944
Deferred income tax expense	—	(6,624,980)
	<u>10,502,748</u>	<u>7,119,918</u>

11.3.6 Dividends

12 DEFINITIONS

[illegible]

司), 15, 2012, -

春康林心理醫院有限公司), 16, 2016,





[illegible]

() – ()

[illegible]

年醫院有限公司), 2, 2015,

6. 下列各句，没有语病的一项是（ ）

 A. 在“中国好声音”第三季总决赛中，李健以一首《贝加尔湖畔》征服了全场的观众。

 B. 随着“中国好声音”第三季总决赛的落幕，李健以一首《贝加尔湖畔》征服了全场的观众。

 C. 随着“中国好声音”第三季总决赛的落幕，李健以一首《贝加尔湖畔》征服了全场的观众。

 D. 随着“中国好声音”第三季总决赛的落幕，李健以一首《贝加尔湖畔》征服了全场的观众。

\$_____ 2017年12月31日，本公司

2017年12月31日，本公司A

2017年12月31日，本公司k

2017年12月31日，本公司

2017年12月31日，本公司k

2017年12月31日，本公司(淮南康寧醫院有限公司)，

22, 2017, 本公司

2017年12月31日，本公司(廊坊怡寧醫院有限公司)，k

2017年12月31日，本公司(廊坊市怡寧醫院管理有限公司)，

2, 2015, 本公司

2017年12月31日，本公司A

2017年12月31日，本公司(台州市路橋慈寧醫院有限公司)，k

2017年12月31日，本公司(台州市路橋怡寧醫院有限公司)，

12, 2016, 本公司

2017年12月31日，本公司A

2017年12月31日，本公司

2017年12月31日，本公司

2017年12月31日，本公司(青田康寧醫院有限公司)，

A 1, 2011, 本公司

2017年12月31日，本公司(衢州怡寧醫院有限公司)，

20, 2015, 本公司

2017年12月31日，本公司30, 2020

Wenzhou Kangning Hospital Co., Ltd. (永嘉康寧醫院有限公司),
12, 2012,
%_

Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili

Ar 28, 2020

